CCL2 and neoplasm: Given that CCR4 deficiency does not affect the infiltration and migration of monocytes, CCR4 inhibition to block the CCL2/CCR4 axis could be a promising novel antitumoral strategy to reduce the risk of rapid tumor recurrence and metastasis during the cessation of CCL2 inhibition treatment.